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Background: Impaired glucose tolerance is present in one third of patients with a TIA or ischemic stroke and is
associated with a two-fold risk of recurrent stroke. Metformin improves glucose tolerance, but often leads to side
effects.
The aim of this study is to explore the feasibility, safety, and effects on glucose metabolism of metformin and
sitagliptin in patients with TIA or minor ischemic stroke and impaired glucose tolerance. We will also assess
whether a slow increase in metformin dose and better support and information on this treatment will reduce the
incidence of side effects in these patients.
Methods/Design: The Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or
minor ischemic Stroke trial (MAAS trial) is a phase II, multicenter, randomized, controlled, open-label trial with
blinded outcome assessment. Non-diabetic patients (n = 100) with a recent (<6 months) TIA, amaurosis fugax or
minor ischemic stroke (modified Rankin scale ≤ 3) and impaired glucose tolerance, defined as 2-hour post-load
glucose levels between 7.8 and 11.0 mmol/L after repeated standard oral glucose tolerance test, will be included.
Patients with renal or liver impairment, heart failure, chronic hypoxic lung disease stage III–IV, history of lactate
acidosis or diabetic ketoacidosis, pregnancy or breastfeeding, pancreatitis and use of digoxin will be excluded. The
patients will be randomly assigned in a 1:1:2 ratio to metformin, sitagliptin or “no treatment.” Patients allocated to
metformin will start with 500 mg twice daily, which will be slowly increased during a 6-week period to a twice daily
dose of 1000 mg. Patients allocated to sitagliptin will be treated with a daily fixed dose of 100 mg. The study has
been registered as NTR 3196 in The Netherlands Trial Register. Primary outcomes include percentage still on treatment,
percentage of (serious) adverse events, and the baseline adjusted difference in 2-hour post-load glucose levels at
6 months.
Discussion: This study will give more information about the feasibility and safety of metformin and sitagliptin as
well as the effect on 2-hour post-load glucose levels at 6 months in patients with TIA or ischemic stroke and
impaired glucose tolerance.
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Impaired glucose tolerance, an intermediate metabolic state
between normal glucose tolerance and diabetes mellitus, is
present in about a third of patients with transient ischemic
attack (TIA) or ischemic stroke [1–4], and is associated
with a two-fold risk of recurrent stroke [5]. The mecha-
nisms underlying this association are not fully understood,
but include insulin resistance, endothelial dysfunction, dys-
lipidemia, chronic inflammation, procoagulability, and im-
paired fibrinolysis [6–8].
Pharmacological interventions reduce the rate of pro-
gression to type 2 diabetes by 10–60 % in people with im-
paired glucose tolerance [9–12]. Lifestyle interventions are
likely to be at least as effective as drug treatment [9, 12],
but are often difficult to carry out successfully, and life-
style advice needs to be reinforced on a regular basis.
There is no clear evidence that tight glycemic control
reduces the risk of stroke in patients with diabetes or
impaired glucose tolerance. A recent meta-analysis on
glucose-lowering pharmacological interventions in patients
with impaired glucose tolerance found no beneficial effects
on all-cause mortality or death due to major cardiovascular
events, with the possible exception of stroke [13].
In the UK Prospective Diabetes Study, however, met-
formin therapy or intensive treatment with sulphony-
lurea or insulin seems to be associated with fewer
cardiovascular events in newly-diagnosed type 2 diabetics
[14]. Furthermore, a large randomized placebo-controlled
trial found that metformin reduces macrovascular com-
plications when added to insulin treatment in type 2
diabetes [15].
However, metformin had no effect on the carotid intima
media-thickness or carotid plaque in stroke patients [16].
Also, metformin was not more effective in preventing
myocardial infarction than other intensive therapy. Fur-
thermore, metformin added to sulphonylurea therapy
was associated with an increased risk for diabetes-
related deaths and all-cause mortality [14]. Metformin is
regarded as one of the most effective drugs for treating
type 2 diabetes. Recent basic research reveals that sup-
pression of hepatic gluconeogenesis by inhibiting mito-
chondrial glycerophosphate dehydrogenase is the main
underlying mechanism of metformin's blood glucose-
lowering effect [17].
Metformin is recommended as first-line treatment in
type 2 diabetes mellitus, and is cheap as compared to
the newer antidiabetic drugs. Our recent findings sug-
gest that metformin treatment is safe in patients with
TIA or ischemic stroke and impaired glucose tolerance,
and probably leads to improved glucose tolerance [18].
However, 50 % of the patients experienced gastrointes-
tinal side effects resulting in permanent discontinuation
in 25 %. Slower increase in dose of metformin and better
information and support on the temporary nature of theside effects might prevent the high incidence of side ef-
fects and discontinuation of treatment respectively.
Novel drugs, like selective dipeptidyl peptidase-4 (DPP-4)
inhibitors for type 2 diabetes, might have fewer side effects
than metformin and other anti-diabetic medication. They
target primarily postprandial glucose, which is more closely
associated with carotid intimal thickness and atheroscler-
osis risk factors than fasting plasma glucose or glycosylated
hemoglobin A1 (HbA1c) levels [19]. Sitagliptin, a selective
DPP-4 inhibitor, improves glycemic control and β-cell func-
tion and has a safety profile similar to placebo, with low risk
of gastrointestinal side effects [20, 21]. Also, it is associated
with weight loss and a lower risk on hypoglycemia [20, 21].
However, some recent trials have shown that DPP-4 inhibi-
tors had no effect on adverse cardiovascular outcomes in
patients with type 2 diabetes [19].
The aim of the study is to explore the feasibility,
safety, and effect on glucose metabolism of both metfor-
min and sitagliptin in patients with TIA or minor ische-
mic stroke and impaired glucose tolerance. Also, we will
assess whether a slow increase in dose of metformin and
better support and information on this treatment will re-
duce the incidence of side effects in these patients.
Methods
Design
We conduct a phase II, multicenter Prospective, Ran-
domized, Open-label, Blinded End-point (PROBE) trial
of standard care plus metformin or sitagliptin, as com-
pared with standard care without antidiabetic treatment.
Patient population – inclusion and exclusion criteria
All adult patients attending the TIA outpatient clinic or
admitted to the stroke unit in 3 hospitals in the
Netherlands with TIA, amaurosis fugax or minor ischemic
stroke (defined as a modified Rankin scale (mRS) [22]
score of 3 or less) within the previous 6 months, and im-
paired glucose tolerance, defined as 2-hour post-load glu-
cose levels between 7.8 and 11.0 mmol/L [23] after
standard oral glucose tolerance test (OGTT) [24], will be
invited to participate in the trial by their neurologist.
The diagnosis of TIA (symptoms < 24 hours) or ische-
mic stroke will be made by a neurologist by standard
guidelines. An ischemic stroke or TIA will be defined as
an episode of neurological dysfunction caused by focal
cerebral or retinal infarction [25]. All patients will undergo
a computed tomography (CT) scan of the brain, electro-
cardiogram, carotid ultrasound imaging and blood investi-
gations, which also includes the lipid profile.
The OGTT will be repeated after 2–6 weeks to rule
out laboratory error and the acute phase effect. If the
second OGTT confirms the diagnosis of impaired glu-
cose tolerance, and all the selection criteria are fulfilled,
the patient will be asked for written informed consent
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be obtained by all participants. Inclusion and exclusion
criteria are shown in Table 1.
Randomization, blinding and treatment allocation
Patients will be randomized by the investigators to receive
either open-label metformin or sitagliptin or “no treat-
ment” in a 1:1:2 ratio for 6 months. The randomization
process will be available online by means of a list gener-
ated by computer before the start of the trial. Treatment
allocation will be only possible after registration in the
database. From this moment, it will not be possible to re-
move a patient from the database. The list with informa-
tion regarding the treatment allocation will be kept
separate from the study database. An independent statisti-
cian, who otherwise will not be involved in the study, will
provide the list. The statistician will report unblinded data
to the Data Safety and Monitoring Board (DSMB) for
evaluation and interim analysis, for monitoring the safety
and progression of the trial. The steering committee will
be kept unaware of these results unless necessary (as
judged by the DSMB), and the code will not be broken
until the last patients have completed the 6-months of
follow-up.
Irrespective of treatment allocation, patients will receive
optimal standard care from the neurologist, including anti-
thrombotic and antihypertensive agents as well asTable 1 Inclusion and exclusion criteria
Inclusion criteria:
Age ≥ 18 years
TIA, amaurosis fugax or minor ischemic stroke (mRS ≤ 3)
Symptom onset < 6 months
Impaired glucose tolerance (2-hour post-load glucose level between
7.8 and 11.0 mmol/L) in 2 consecutive measurements
Exclusion criteria:
Diabetes mellitus
History of diabetic ketoacidosis
Symptoms of type 1 diabetes
Signs of renal impairment (creatinine of 135 μmol/L or higher for
men, and 110 μmol/L or higher for women)
Known liver disease or disturbed liver function tests (alanine amino
transferase, aspartate amino transferase, alkaline phosphatase, or
γ-glutamyl transferase increased to more than twice the upper limit
of typical values)
History of lactic acidosis
Heart failure requiring pharmacological therapy
Pancreatitis
Chronic hypoxic lung disease stages III–IV
Digoxin use
Pregnancy or breastfeeding
mRS modified Rankin Scale, TIA transient ischemic attackcholesterol- lowering drugs, where appropriate [26]. In
addition, a stroke nurse specialist will provide general life-
style advice including healthy diet, stopping smoking, and
regular physical exercise. These interventions will also be
monitored by the investigators through the follow-up
contacts.Intervention
Patients will be randomly allocated to open-label metfor-
min or sitagliptin or “no treatment” for a 6-month
period. The treatment assignment is concealed. Patients
allocated to metformin will start with 500 mg twice
daily, which will be slowly increased in a 6-week period
to 1000 mg twice daily (week 1: 2 times 500 mg, week 3:
2 times 850 mg, week 7: 2 times 1000 mg). If there are
unmanageable side effects at an increased dose, the
lower dose will be resumed and the increase will be tried
again the next week. Patients allocated to sitagliptin will
be treated with a daily fixed dose of 100 mg.Study procedures
All patients will be assessed at baseline, and at 6 months.
At baseline, data on clinical features of TIA or ischemic
stroke, demographic data, medical history, vascular risk
factors, and medication use will be obtained.
At the follow-up visit, patients will be asked to
complete a single questionnaire to determine compli-
ance and nature of any of the side effects of the study
medication. Patients will also be contacted by telephone
for recording of possible adverse events and to support
continuation of treatment at 2 weeks, 6 weeks, and 3
months after inclusion. If necessary (e.g. in case of un-
manageable side effects), the number of telephone con-
tacts and or follow-up visits will be intensified. Before
randomization and at 6 months, all patients will undergo
an OGTT with 75 g of glucose. Fasting glucose levels,
body mass index (BMI), waist circumference, blood
pressure and lipid profile will be assessed at baseline,
and at 6 months (Fig. 1).
Patients will be excluded from other trials which in-
volve any secondary prevention treatment of stroke like
new medication or lifestyle adjustments. The final raters
who will assess the outcome measures will be blinded
for treatment allocation.Primary outcomes
The primary outcomes are tolerability of metformin and
sitagliptin, assessed as the number of patients still on
treatment after 6 months, the number of adverse events
and serious adverse events, and the baseline adjusted dif-
ference in 2-hour post-load glucose levels.
Fig. 1 Flowchart study design
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Secondary outcomes are the effect of metformin and
sitagliptin on fasting plasma glucose levels at 6 months,
the percentage of patients with normal glucose tolerance
at 6 months and on the BMI and waist circumference at
6 months.
Data safety monitoring board
The DSMB is composed of independent experts in the
field of statistics, neurology, and vascular internal medi-
cine. It monitors the progress and safety of the trial, and
performs an interim analysis. Based on this information,
they advise the steering committee on pre-specified
grounds, as formulated by the DSMB.
Sample size
We expect that 50 % of patients on metformin will experi-
ence side effects during follow-up. Assuming a difference
of 40 % in side effects between patients on metformin and
patients in the control group, and a difference of 30 % be-
tween patients on metformin and patients on sitagliptin,
100 patients will have a power of 80 % to detect a signifi-
cant (α = 0.05) difference in side effects.
A sample size of 100 patients, calculated by a statisti-
cian, (25 on metformin, 25 on sitagliptin, and 50 in the
control group) will provide a power of 80 %, to detect a
difference of 8 % in 2-hour post-load glucose level after
6 months between treatment groups, assuming a signifi-
cance level of α = 0.05 and a mean glucose level of 9.0
mmol/L in the control group, with a standard deviation
of 1.0 mmol/L.Statistical analyses
Analyses will be done by intention-to-treat and all pa-
tients who are randomly assigned to treatment will be
included in the pre-specified analyses. The effect in each
of the two treatment groups will be compared to the
control group separately.
We will estimate the baseline adjusted differences in
mean 2-hour post-load glucose levels and fasting glucose
levels between treatment groups with 95 % confidence
intervals (CIs) with univariable linear regression. Adjust-
ments will be made with a multivariable linear regres-
sion model that will include the following factors: age,
sex, time to treatment, and baseline waist. Similar ana-
lyses will be performed to study the effect of treatment
with metformin or sitagliptin on BMI and waist circum-
ference. We will compare the percentage of patients still
on treatment after 6 months, the incidence of (serious)
adverse events and percentage of patients with a normal
glucose tolerance at 6 months between treatment groups
with chi-square test.
No adjustment for multiplicity will be done due to the
explanatory nature of a phase II trial.
Ethical approval
The Medical Ethical Trial Commissions (METC) of both
the Erasmus Medisch Centrum in Rotterdam and Medisch
Spectrum Twente in Enschede gave approval for this trial.
Discussion
Impaired glucose tolerance is present in up to one third
of patients with TIA or stroke and is associated with a
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creased risk of impaired glucose tolerance could be due
to the impaired lipid profile of these patients. However,
there is an independent association of impaired glucose
tolerance with cardiovascular diseases. Intensive glucose
control with oral antidiabetic drugs reduces the rate of
progression to type 2 diabetes in patients with impaired
glucose tolerance [9–12]. Whether pharmacotherapeutic
intervention reduces the risk of cardiovascular events in
patients with TIA or minor ischemic stroke (who are
often older with more co-medication) and impaired glu-
cose tolerance is unknown. Our recent study (LIMIT)
has shown that metformin treatment is safe and im-
proves glucose tolerance in these patients, but often
leads to gastrointestinal side effects [18].
The rationale for choosing metformin and sitagliptin is
as follows: metformin is recommended as first-line treat-
ment in type 2 diabetes, is cheap, and widely used in
The Netherlands. However, in the LIMIT trial metfor-
min caused frequent gastrointestinal side effects and
consequently discontinuation of drug adherence in a
large percentage of the patients [18]. When slow in-
crease in dose of metformin and better support and in-
formation on this treatment proves to reduce the
incidence of side effects in these patients, metformin will
be a cheap, easy and widely used drug to improve glu-
cose tolerance in a large proportion of stroke patients.
Sitagliptin has proven to be equally effective and safe as
metformin, with improvement of glycemic control by
lowering HbA1c levels, and a lower risk of gastrointes-
tinal side effects and hypoglycemia [20, 21]. This com-
bined with the once daily, fixed dose makes it a patient-
friendly drug and is more prone to good adherence.
However, the costs of sitagliptin are more than 16 times
higher compared to metformin. To compare the effect
in both treatment groups with the control group separ-
ately, a randomization ratio of 1:1:2 was chosen.
Although a double-blind, placebo-controlled designed
trial would have been superior, the current trial has a
PROBE design. The main reason is that the former comes
with greater costs. Potential limitations are therefore the
lack of a placebo group and its open design, which can
give an increased risk on performance bias. However, out-
come assessment will be blinded for treatment allocation.
The final raters who will assess the outcome will be
blinded for treatment allocation. And the design will re-
semble the effect in clinical practice after implementation.
Although lifestyle intervention is equally effective in
lowering glucose levels as glucose- lowering drugs, it is
hard to sustain [9, 12]. If we can prove with the MAAS
trial that metformin and/or sitagliptin are safe and feas-
ible in lowering glucose levels, a phase III trial is neces-
sary to investigate the effect on the incidence of
recurrent stroke and other cardiovascular complications,to improve secondary prevention in these patients. In
this phase III trial, patients with a TIA or minor ische-
mic stroke and impaired glucose tolerance will receive
standard care and be allocated to metformin or sitaglip-
tin, depending on the results of this phase II-trial, and
one of these will be compared to placebo.
Trial status
The MAAS trial started in January of 2014. Thirty-two
patients have been included so far.
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